The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications

  • Shin, Junghoon (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Koh, Youngil (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Youk, Jeonghwan (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Kim, Miso (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Kim, Byung Soo (Department of Internal Medicine, Korea University College of Medicine) ;
  • Choi, Chul Won (Department of Internal Medicine, Korea University College of Medicine) ;
  • Sung, Hwa Jung (Department of Internal Medicine, Korea University College of Medicine) ;
  • Park, Yong (Department of Internal Medicine, Korea University College of Medicine) ;
  • Yoon, Sung-Soo (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine) ;
  • Kim, Inho (Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine)
  • Received : 2016.08.03
  • Accepted : 2017.02.04
  • Published : 2017.07.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population. Methods: We reviewed the medical records of MM patients whose age was 40 years or younger at diagnosis. Results: A total of 32 patients were analyzed (male to female ratio 19:13, median age 37 years). According to International Staging System, 29%, 48%, and 16% were in stage I, II, and III, respectively. Light chain myeloma accounted for 30%. Clinically significant anemia, hypercalcemia, azotemia, and hypoalbuminemia were present in 29%, 28%, 13%, and 28%, respectively. Three or more lytic bone lesions were detected in 45% of the patients, whereas 13% had no lytic bone lesions. Regarding treatment, 79% of patients received autologous hematopoietic stem cell transplantation. After a median follow-up duration of 64 months, the 1-, 3-, and 5-year overall survival (OS) rates were 84%, 62%, and 54%, respectively. The median OS was 61 months for the entire cohort. Conclusions: In our study, MM patients aged 40 years or younger at diagnosis showed no superior survival compared to those of the moderately elderly patients based on historical data.

Keywords

References

  1. Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells 1995;13 Suppl 2:1-9.
  2. Corso A, Klersy C, Lazzarino M, Bernasconi C. Multiple myeloma in younger patients: the role of age as prognostic factor. Ann Hematol 1998;76:67-72. https://doi.org/10.1007/s002770050365
  3. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998;30:493-501. https://doi.org/10.3109/10428199809057562
  4. Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group. Blood 2008;111:4039-4047. https://doi.org/10.1182/blood-2007-03-081018
  5. Dimopoulos MA, Pouli A, Anagnostopoulos A, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma 2006;47:1553-1556. https://doi.org/10.1080/10428190600647723
  6. Solves P, de la Rubia J, Jarque I, et al. Liver disease as primary manifestation of multiple myeloma in a young man. Leuk Res 1999;23:403-405. https://doi.org/10.1016/S0145-2126(98)00168-4
  7. Hogan MC, Lee A, Solberg LA, Thome SD. Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. Am J Hematol 2002;70:55-59. https://doi.org/10.1002/ajh.10077
  8. Cheema PK, Zadeh S, Kukreti V, et al. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant. Biol Blood Marrow Transplant 2009;15:686-693. https://doi.org/10.1016/j.bbmt.2009.02.013
  9. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells 1995;13 Suppl 2:56-63.
  10. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013;121:884-892. https://doi.org/10.1182/blood-2012-05-432203
  11. Chretien ML, Hebraud B, Cances-Lauwers V, et al. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica 2014;99:1236-1238. https://doi.org/10.3324/haematol.2013.098608
  12. Kim K, Lee JH, Kim JS, et al. Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study. Am J Hematol 2014;89:751-756. https://doi.org/10.1002/ajh.23731
  13. Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 2010;89:201-206. https://doi.org/10.1007/s00277-009-0807-6
  14. Ailawadhi S, Aldoss IT, Yang D, et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol 2012;158:91-98. https://doi.org/10.1111/j.1365-2141.2012.09124.x
  15. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118:3205-3211. https://doi.org/10.1182/blood-2011-06-297853
  16. Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012;26:349-355. https://doi.org/10.1038/leu.2011.204
  17. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996;93:345-351. https://doi.org/10.1046/j.1365-2141.1996.5191061.x
  18. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883. https://doi.org/10.1056/NEJMoa022340

Cited by

  1. Bone marrow transplant and pediatric multiple myeloma vol.66, pp.2, 2019, https://doi.org/10.1002/pbc.27528
  2. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience vol.138, pp.25, 2017, https://doi.org/10.1182/blood.2021011285